Relevância clínica do monitoramento terapêutico de fármacos para amicacina e gentamicina
DOI:
https://doi.org/10.5902/2236583474576Palavras-chave:
Aminoglicosídeos, Efeitos adversos, Infecção, AntibióticosResumo
Antibióticos aminoglicosídeos (AG) são amplamente prescritos no tratamento de infecções bacterianas graves em pacientes neonatos, idosos e críticos. Considerando o aumento global na resistência a antimicrobianos, é necessário o uso de estratégias para evitar este problema, otimizando os recursos disponíveis. O monitoramento terapêutico de fármacos (MTF) permite a individualização de dose e ajuda a prevenir eventos adversos relacionados a sub ou sobredosagem. Neste sentido, o objetivo desta revisão foi analisar as evidências científicas na literatura sobre a importância clínica do MTF para AG, abordando dados quanto aos seus benefícios, abrangendo os principais pontos relacionados a essa prática, fornecendo uma visão geral do assunto. As databases PubMed e Science Direct foram consultadas utilizando para a busca os termos: “therapeutic drug monitoring” e “aminoglycosides”, limitando para artigos publicados entre 2015 e 2022. Ao todo, 26 artigos foram incluídos nesta revisão. O MTF parece beneficiar especialmente os pacientes idosos, neonatos e críticos, com concentrações alvo e tempos de coleta bem estabelecidos, sendo que o alvo terapêutico mais recomendado é o Cmáx/CIM > 8. Porém, o treinamento e conhecimento da equipe envolvida é essencial para a implementar e interpretar o MTF adequadamente.
Downloads
Referências
Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020 Jun;46(6):1127–53.
de Velde F, Mouton JW, de Winter BCM, van Gelder T, Koch BCP. Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. Pharmacol Res. 2018 Aug;134:280–8.
Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012 Jan;73(1):27–36.
Šíma M, Bakhouche H, Hartinger J, Cikánková T, Slanař O. Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance. Eur J Hosp Pharm. 2017 Oct 30;ejhpharm-2017-001396.
Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J. 2011 Jun;41(6):441–9.
Sadeghi K, Hamishehkar H, Najmeddin F, Ahmadi A, Hazrati E, Honarmand H, et al. High-dose amikacin for achieving serum target levels in critically ill elderly patients. Infect Drug Resist. 2018 Feb 13;11:223–8.
van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JGW, van Soolingen D, et al. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017 Mar;61(3).
Ben Romdhane H, Ben Fredj N, Chaabane A, Ben Aicha S, Chadly Z, Ben Fadhel N, et al. Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen. Nephrol Ther. 2019 Apr;15(2):110–4.
van Maarseveen EM, Sprij A, Touw DJ. Extended-Interval Dosing of Gentamicin Aiming for a Drug-Free Period in Neonates: A Prospective Cohort Study. Ther Drug Monit. 2016 Jun;38(3):402–6.
Craig WA. Optimizing aminoglycoside use. Crit Care Clin. 2011 Jan;27(1):107–21.
Smits A, De Cock RFW, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CAJ. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. Antimicrob Agents Chemother. 2015 Oct;59(10):6344–51.
Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojeńska A, Kübler A. Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013 Jul 25;17(4):R165.
Kato H, Hagihara M, Hirai J, Sakanashi D, Suematsu H, Nishiyama N, et al. Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen. Drugs R D. 2017 Mar;17(1):177–87.
Germovsek E, Barker CI, Sharland M. What do I need to know about aminoglycoside antibiotics? Arch Dis Child Educ Pract Ed. 2017 Apr;102(2):89–93.
Cristea S, Smits A, Kulo A, Knibbe CAJ, van Weissenbruch M, Krekels EHJ, et al. Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia. Antimicrob Agents Chemother. 2017 Dec;61(12).
Kovačević T, Avram S, Milaković D, Špirić N, Kovačević P. Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients. J Basic Clin Pharm. 2016 Jun;7(3):65–9.
Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant infections and COVID-19. Nat Rev Microbiol. 2020 Aug;18(8):409–10.
Page, McKenzie, Bossuyt, Boutron, Hoffmann, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
Endo A, Nemoto A, Hanawa K, Maebayashi Y, Hasebe Y, Kobayashi M, et al. Relationship between amikacin blood concentration and ototoxicity in low birth weight infants. J Infect Chemother. 2019 Jan;25(1):17–21.
Jayakumar I, Mathaiyan J, Mandal J, Deepanjali S, Sreenivasan SK. Impact of Therapeutic Drug Monitoring on Once-Daily Regimen of Amikacin in Patients With Urinary Tract Infection: A Prospective Observational Study. Ther Drug Monit. 2020 Dec;42(6):841–7.
Namazi S, Sagheb MM, Hashempour MM, Sadatsharifi A. Usage pattern and serum level measurement of amikacin in the internal medicine ward of the largest referral hospital in the south of iran: A pharmacoepidemiological study. Iran J Med Sci. 2016 May;41(3):191–9.
White BP, Lomaestro B, Pai MP. Optimizing the initial amikacin dosage in adults. Antimicrob Agents Chemother. 2015 Nov;59(11):7094–6.
Bialkowski S, Staatz CE, Clark J, Lawson R, Hennig S. Gentamicin Pharmacokinetics and Monitoring in Pediatric Patients with Febrile Neutropenia. Ther Drug Monit. 2016 Dec;38(6):693–8.
Plajer SM, Chin PKL, Vella-Brincat JWA, Buffery PJ, Begg EJ. Gentamicin and renal function: lessons from 15 years’ experience of a pharmacokinetic service for extended interval dosing of gentamicin. Ther Drug Monit. 2015 Feb;37(1):98–103.
Boyer A, Timsit J-F, Klouche K, Canet E, Phan T-N, Bohé J, et al. Aminoglycosides in critically ill septic patients with acute kidney injury receiving continuous renal replacement therapy: A multicenter, observational study. Clin Ther. 2021 Jun;43(6):1116–24.
Carrié C, Delzor F, Roure S, Dubuisson V, Petit L, Molimard M, et al. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy. Antimicrob Agents Chemother. 2020 Mar 24;64(4).
Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother. 2021 Feb;27(2):256–61.
Muller A, Leroy J, Patry I, Hénon T, Hocquet D, Chirouze C, et al. Appropriateness of aminoglycoside prescriptions in a French university hospital. Med Mal Infect. 2016 Sep;46(6):308–13.
Al Za’abi M, Al Muqbali J, Al-Waili K. Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman. Saudi Pharm J. 2015 Sep;23(4):458–62.
McCudden CR. Quality, origins and limitations of common therapeutic drug reference intervals. Diagnosis (Berl). 2018 Jun 27;5(2):47–61.
Pérez-Blanco JS, Sáez Fernández EM, Calvo MV, Lanao JM, Martín-Suárez A. Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach. J Antimicrob Chemother. 2020 Aug 1;75(8):2222–31.
Ruiz J, Ramirez P, Company MJ, Gordon M, Villarreal E, Concha P, et al. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients. J Glob Antimicrob Resist. 2018 Mar;12:90–5.
Pérez-Blanco JS, Sáez Fernández EM, Calvo MV, Lanao JM, Martín-Suárez A. Evaluation of current amikacin dosing recommendations and development of an interactive nomogram: the role of albumin. Pharmaceutics. 2021 Feb 15;13(2).
EUCAST E committe on antimicrobial susceptibility testing. Gentamicin Rationale for the EUCAST clinical breakpoints, version 2.0. 2020.
Hitron AE, Sun Y, Scarpace SB. Accuracy of empiric gentamicin dosing guidelines in neonates. J Pediatr Pharmacol Ther. 2010 Oct;15(4):264–73.
Roger C, Louart B, Elotmani L, Barton G, Escobar L, Koulenti D, et al. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Ann Intensive Care. 2021 Mar 19;11(1):49.
Kato H, Parker SL, Roberts JA, Hagihara M, Asai N, Yamagishi Y, et al. Population pharmacokinetics analysis of amikacin initial dosing regimen in elderly patients. Antibiotics (Basel). 2021 Jan 20;10(2).
Fuchs A, Zimmermann L, Bickle Graz M, Cherpillod J, Tolsa J-F, Buclin T, et al. Gentamicin exposure and sensorineural hearing loss in preterm infants. PLoS ONE. 2016 Jul 8;11(7):e0158806.
Gonzalez J, Ahern J, Noyes E, Corriveau M, Mercier C. Identification of risk factors for elevated neonatal gentamicin trough concentrations. J Pediatr Pharmacol Ther. 2016 Apr;21(2):133–9.
Hughes KM, Johnson PN, Anderson MP, Sekar KC, Welliver RC, Miller JL. Comparison of amikacin pharmacokinetics in neonates following implementation of a new dosage protocol. J Pediatr Pharmacol Ther. 2017;22(1):33–40.
Singu BS, Mubita M, Thikukutu MM, Mufenda JK, McKenzie SB, Verbeeck RK. Monitoring of gentamicin serum concentrations in obstetrics and gynaecology patients in Namibia. Int J Clin Pharm. 2018 Jun;40(3):520–5.
Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant J-Y, et al. Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2016 Aug;60(8):4901–9.
Taccone FS, de Backer D, Laterre P-F, Spapen H, Dugernier T, Delattre I, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2011 Jun;37(6):531–5.
Sabur NF, Brar MS, Wu L, Brode SK. Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB). BMC Infect Dis. 2021 Mar 10;21(1):254.
Hodiamont CJ, Juffermans NP, Bouman CSC, de Jong MD, Mathôt RAA, van Hest RM. Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. Int J Antimicrob Agents. 2017 Feb;49(2):204–11.
du Toit M, Burger JR, Rakumakoe DM, Rheeders M. Standards of aminoglycoside therapeutic drug monitoring in a South African private hospital: perspectives and implications. Ghana Med J. 2019 Mar;53(1):8–12.
Ryan AC, Carland JE, McLeay RC, Lau C, Marriott DJE, Day RO, et al. Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing. Br J Clin Pharmacol. 2021 Mar;87(3):1422–31.
Dvořáčková E, Pávek P, Kováčová B, Rychlíčková J, Suchopár O, Hojný M, et al. Is computer-assisted aminoglycoside dosing managed by a pharmacist a safety tool of pharmacotherapy? Physiol Res. 2019 Nov 22;68(Suppl 1):S87–96.
Alhameed AF, Khansa SA, Hasan H, Ismail S, Aseeri M. Bridging the Gap between Theory and Practice; the Active Role of Inpatient Pharmacists in Therapeutic Drug Monitoring. Pharmacy (Basel). 2019 Feb 18;7(1).
Jaiswal S, Agarwal A, Singh SP, Mohan P. Therapeutic drug monitoring of Amikacin in hospitalized patients: A pilot study. Medical Journal Armed Forces India. 2022.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Nadine Arnold Steffens, Rodrigo Redel Petreceli, Roselaine Lima da Vida, Gabrielle Lima Corrêa , Estevan Sonego Zimmermann, Natalia Brucker
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Direito autoral (Copyright): todo o conteúdo do periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/deed.pt_BR/.
A Declaração de Direito Autoral e os itens a serem observados podem ser visualizados abaixo:
1. Política para Periódicos de Acesso Livre
Autores que publicam nesta revista concordam com os seguintes termos:
a) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
b) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
c) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).
Todo o conteúdo do periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/deed.pt_BR/.
